Open questions in valvular heart disease 1157 its prevalence, severity and form of valvular disease and, in a follow-up study, to evaluate how these findings changed up to five years later. Methods: A systematic cross-sectional echocardiographic screening study was performed in 3062 randomly selected schoolchildren, aged 5 to 15 years, in Aswan, Egypt. The diagnosis of RHD was based on the current WHF criteria and the images obtained were reviewed by two senior cardiologists. Follow-up of children with a definite or possible diagnosis of RHD together and a control group of 80 normal children was carried out 48 to 60 months later using the same techniques. The initial screening was carried out when the children were aged 10±2.6 years, with a slight male predominance (58.7%, n=1796). Sixty children were diagnosed with definite RHD (19.6 per 1000) and 35 with possible disease (11.4 per 1000). Most children had mitral valve disease (n=68, 97.1%). Of the 72 children followed up progression was documented in 14 children (19.4%) and regression in 30 (41.7%) children. Rates of progression and regression were related to both gender and age. Boys had lower rates of progression while older children had lower rates of regression (regression was seen in 23 out of 30 children (76.7%) studied at the age of 10-15 years compared to only 7 out of 30 (23.3%) in the age group 16-19 years, P<0.001). Children with functional defects of the valve also tended to show lower rates of progression than the children with structural changes. The 72 cases of possible or definite RHD were stratified into two subgroups based on the presence or absence of MR. Of the 57 cases with MR, nine (16%) had progression of their disease compared with five out of fifteen (33%) cases who did not have MR, of which four had definite RHD. Conclusions: Our study shows a high prevalence of subclinical RHD in school children in urban Aswan. Although a high proportion of the abnormalities originally detected persisted at follow-up, both progression and regression of valve lesions was demonstrated. Disease progression and regression seem related to gender, age and the presence of initial mitral regurgitation. Background: Mitral regurgitation (MR) is the most frequent valvular disease in the community. However, the current knowledge and application of Guidelines on diagnosis and evaluation of MR are not well known. Purpose: The Education Committee of the ESC and AXDEV Group performed a mixed-methods educational needs assessment, which included a case-based evaluation, in a wide panel of practitioners in Europe. Methods: The quantitative portion of the needs assessment included 3 case scenarios (asymptomatic severe primary MR, symptomatic severe primary MR in the elderly and symptomatic severe secondary MR) and was conducted online from March to May 2016 in 7 countries: France, Germany, Italy, Poland, Spain, Sweden and the United Kingdom. 554 practitioners participated in the study, 51 in the exploratory qualitative phase, and 503 in the quantitative phase. The quantitative phase case scenarios were answered by 108 primary care physicians (PCP), 203 general and 192 sub-specialized cardiologists. Results: Cardiac auscultation was performed systematically by 54% of PCPs and only in the presence of cardiac symptoms by 31%. In addition, 40% of PCPs did not perform systematic auscultation after mitral valve repair. 20% of PCPs considered that the lack of symptoms was discordant with severe MR. In an elderly patient with severe MR and comorbidities, dyspnoea was more frequently considered as severe by PCPs (69% of participants) than by cardiologists (29% of participants). Cardiologists appropriately interpreted echocardiographic findings with regards to mechanism and quantitation of symptomatic primary MR (75% and 75%, respectively) and of asymptomatic primary MR (87% and 86%, respectively). The diagnosis of secondary MR was correct in 93% of cases, although it was based on left ventricular dysfunction in 79% of cases and on analysis of leaflet structure and movement in only 14%. In contrast, secondary MR was quantitated as severe by only 44% of cardiologists. Only 44% of cardiologists requested the measurement of tricuspid annulus diameter before surgery for asymptomatic severe primary MR.
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Background: Mitral regurgitation (MR) is the most frequent valvular disease in the community. However, the current knowledge and application of Guidelines on diagnosis and evaluation of MR are not well known. Purpose: The Education Committee of the ESC and AXDEV Group performed a mixed-methods educational needs assessment, which included a case-based evaluation, in a wide panel of practitioners in Europe. Methods: The quantitative portion of the needs assessment included 3 case scenarios (asymptomatic severe primary MR, symptomatic severe primary MR in the elderly and symptomatic severe secondary MR) and was conducted online from March to May 2016 in 7 countries: France, Germany, Italy, Poland, Spain, Sweden and the United Kingdom. 554 practitioners participated in the study, 51 in the exploratory qualitative phase, and 503 in the quantitative phase. The quantitative phase case scenarios were answered by 108 primary care physicians (PCP), 203 general and 192 sub-specialized cardiologists. Results: Cardiac auscultation was performed systematically by 54% of PCPs and only in the presence of cardiac symptoms by 31%. In addition, 40% of PCPs did not perform systematic auscultation after mitral valve repair. 20% of PCPs considered that the lack of symptoms was discordant with severe MR. In an elderly patient with severe MR and comorbidities, dyspnoea was more frequently considered as severe by PCPs (69% of participants) than by cardiologists (29% of participants). Cardiologists appropriately interpreted echocardiographic findings with regards to mechanism and quantitation of symptomatic primary MR (75% and 75%, respectively) and of asymptomatic primary MR (87% and 86%, respectively). The diagnosis of secondary MR was correct in 93% of cases, although it was based on left ventricular dysfunction in 79% of cases and on analysis of leaflet structure and movement in only 14%. In contrast, secondary MR was quantitated as severe by only 44% of cardiologists. Only 44% of cardiologists requested the measurement of tricuspid annulus diameter before surgery for asymptomatic severe primary MR.
Conclusions:
The early detection of primary MR in asymptomatic patients suffers from the underuse of systematic auscultation by PCPs. Systematic auscultation is also insufficiently performed during follow-up after mitral valve repair. Symptom perception differs between PCPs and cardiologists. Interpretation of echocardiography by cardiologists is good for primary MR but less satisfying for secondary MR, in particular concerning quantitation. Increased awareness is needed on the tricuspid valve. These findings identify important targets for future educational programmes. Acknowledgement/Funding: Abbott, Edwards Lifesciences P5444 | BEDSIDE Heart valvular calcifications as independent predictors of contrast-induced nephropathy and impairment of renal function in patients undergoing cardiac catheterization
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Background: Heart valvular calcifications represent clinical markers of increase cardiovascular risk and growing evidences highlight calcifications as a regulated process related to systemic subclinical vascular endothelium dysfunction. Purpose: We tested the hypothesis that the presence of valvular calcifications (defined as bright echoes of more than 1mm on transthoracic echocardiography) may represent a red flag indicating patients at high risk of renal impairment, when exposed to intravenous iodinated contrast. Methods: We enrolled patients admitted for cardiac catheterization for emergency or elective procedures. The end-points were the onset of contrast-induced nephropathy (CIN) and the impairment of renal function (IRF) during a mean follow-up of 14±7 months (defined as a reduction of at least 25% of eGFR). Results: Thirty-eight patients (11.7%) experienced CIN. Age, high end-diastolic volume, reduced ejection fraction and valvular calcifications showed higher odds of CIN onset, but only calcifications were independently exposed on adjusted analysis (OR: 5.92; 95% IC: 2.6-13.4; p<0.0001). Fifty-two patients (16%) showed IRF. Only valvular calcifications at baseline was markedly higher in patients with IRF than in those without (57% vs 29%; p=0.002). IRF probability was higher in patients with valvular calcifications (p=0.0005 by the log-rank test). The presence of valvular calcifications and the onset of CIN after heart catheterization were significantly associated with IRF on unadjusted and adjusted Cox regression analysis (HR: 2.41; 95% IC: 1.15-5; p=0.01 and HR: 3.2; 95% IC 1.44-7.1; p=0.004 respectively). Results: This asymptomatic cohort had 40% of men, 46% of ≥80 years of age, 35% of hypertension and 20% of atrial fibrillation. There were 262 asymptomatic patients with very severe AS. Compared with 1255 others as control group, patients with very severe AS were older (80±10 versus 77±9 years old), more often had women (71 versus 58%), and had a more critical stenosis on echocardiography (Vmax, 4.5±0.8 versus 3.6±0.6 m/s; PG, 50±17 versus 30±11 mmHg; AVA, 0.55±0.12 versus 0.84±0.11 cm 2 ). During follow-up, patients with very severe AS had higher all-cause mortality (47 versus 33%; p<0.001), more cardiovascular death (32 versus 19%; p<0.001) and a higher likelihood (41 versus 31%; p<0.001) of developing symptoms. There were no significant differences in sudden death (6 versus 5%) and AVR (26 versus 25%). Estimated survival rates were significantly worse for patients with very severe AS: 85%, 73%, 64% and 42% at 1, 2, 3, and 5 years, respectively, compared with 88%, 81%, 74% and 62% for control group (p<0.001).
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Conclusions:
The long-term outcome of asymptomatic, very severe AS patients was poor, though guidelines recommend a watchful waiting in practice. Initial AVR strategy could improve clinical outcomes. Background: Symptoms of mitral stenosis (MS) are worsened during tachycardia and exercise. Beta-blockers are used in controlling heart rate (HR) in MS, resulting in symptom improvement, but come with significant side effects. Ivabradine has a selective action on the sinus node devoid of the usual side effects of beta blockers. Small studies have recently investigated the role of ivabradine in mitral stenosis in sinus rhythm. Research question: Among patients with mitral stenosis in sinus rhythm, is ivabradine comparable to beta-blockers in terms of exercise duration, maximum HR achieved, resting HR, mean gradient, and working capacity? Objectives: Determine the efficacy of ivabradine, compared to beta-blockers, in terms of exercise duration, maximum HR achieved, resting HR, mean gradient, and working capacity among patients with mitral stenosis in sinus rhythm? Methods: We conducted a systematic search of studies using MEDLINE, Google Scholar, ScienceDirect, Scopus, Clinical Key, Cochrane, and clinicaltrials.gov databases in all languages and examined reference lists of studies. We included studies if they are 1) randomized controlled trials comparing ivabradine and beta blockers; 2) of adults >19 years old with mitral stenosis in sinus rhythm; and 3) reported data on exercise duration, maximum HR achieved, resting HR, mean gradient, and working capacity. Studies identified were assessed for risk of bias using the Cochrane Collaboration Tool for Assessing Risk of Bias. We used inverse variance analysis of fixed effects to compute for mean difference, carried out using Review Manager (RevMan) 5.3. Results: Pooled analysis from five identified trials showed that among patients with mitral stenosis in sinus rhythm, ivabradine was better compared to beta blockers in total exercise duration [mean difference 32.73 seconds (95% CI 12.19, 53.27; p=0.002 
P5446 | BEDSIDE
